Standout Papers

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience 2017 2026 2020 2023 380
  1. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience (2017)
    Gilles Salles, Martin Barrett et al. Advances in Therapy

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study
2025 Standout
2 intermediate papers

Works of Martin Barrett being referenced

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
2017
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
2017 Standout

Author Peers

Author Last Decade Papers Cites
Martin Barrett 303 186 318 195 17 654
U. Winkler 304 266 211 362 12 771
S. Poppema 445 184 265 261 15 689
CJ Meijer 310 150 243 239 15 600
Wilhelmina M. Aarts 351 226 244 361 13 723
MJ Brisco 341 228 226 171 9 702
T. Al Saati 419 133 287 153 21 592
Dorfman Rf 452 168 279 153 27 676
M.T. Rivano 277 144 186 116 18 577
H Peng 591 191 241 159 12 779
Lydia M. Evans 240 85 198 260 16 635

All Works

Loading papers...

Rankless by CCL
2026